STRYKER CORP 10-K — AI Bull & Bear Analysis

The 2025 10-K presents a company at a crossroads between technological dominance and financial fragility. While Stryker has successfully expanded its market share in robotics and vascular health, the cost of this growth is a heavily leveraged balance sheet. The transition to a recurring revenue model is promising, but the execution is shadowed by admitted failures in internal financial controls. Ultimately, the investment case hinges on whether the operational momentum in the MedSurg and Neurotechnology segments can outpace the cost of servicing its massive debt. Investors must weigh the high-growth potential of the platformization strategy against the systemic risks posed by single-source dependencies and looming debt maturities.